Molecular basis for the increased polymyxin susceptibility of Klebsiella pneumoniae strains with under-acylated lipid A

Innate Immunity

Volumn 19, Issue 3, 2013, Pages 265-277

  Velkov, Tony ^a   Soon, Rachel L ^a   Chong, Pei L ^a   Huang, Johnny X ^b   Cooper, Matthew A ^b   Azad, Mohammad A K ^a   Baker, Mark A ^c   Thompson, Philip E ^a   Roberts, Kade ^a   Nation, Roger L ^a   Clements, Abigail ^d   Strugnell, Richard A ^e   Li, Jian ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Klebsiella pneumoniae; lipopolysaccharide; Polymyxin

Indexed keywords

COLISTIN; LIPID A; POLYMYXIN B; ANTIINFECTIVE AGENT; FATTY ACID; OUTER MEMBRANE PROTEIN;

ACYLATION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MEMBRANE; DRUG BINDING; ISOTHERMAL TITRATION CALORIMETRY; KLEBSIELLA PNEUMONIAE; MEMBRANE PERMEABILITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTER MEMBRANE; PROTON NUCLEAR MAGNETIC RESONANCE; WILD TYPE; CELL MEMBRANE PERMEABILITY; CHEMISTRY; COMPUTER SIMULATION; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; KLEBSIELLA INFECTIONS; METABOLISM; MUTATION; STRUCTURE ACTIVITY RELATION;

ACYLATION; ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; CELL MEMBRANE PERMEABILITY; COLISTIN; COMPUTER SIMULATION; FATTY ACIDS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LIPID A; MUTATION; POLYMYXIN B; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84877749054     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425912459092     Document Type: Article

References (46)

1. Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev. 1998 ; 11: 589-603
2. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol. 2009 ; 30: 1180-1185
3. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis. 2011 ; 11: 355-362
4. Sidjabat H, Nimmo GR, Walsh TR, et al. Carbapenem resistance in Klebsiella pneumoniae due to the New Delhi Metallo-beta-lactamase. Clin Infect Dis. 2011 ; 52: 481-484
5. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2011 ; 10: 597-602
6. Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother. 2007 ; 60: 1206-1215
7. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect. 2006 ; 12: 315-321
8. Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother. 2005 ; 56: 128-132
9. Elemam A, Rahimian J, Mandell W. Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin Infect Dis. 2009 ; 49: 271-274
10. Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev. 2003 ; 67: 593-656
11. Nikaido H. Outer membrane barrier as a mechanism of antimicrobial resistance. Antimicrob Agents Chemother. 1989 ; 33: 1831-1836
12. Velkov T, Thompson PE, Nation RL, Li J. Structure-activity relationships of polymyxin antibiotics. J Med Chem. 2010 ; 53: 1898-1916
13. Hancock REW, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother. 1999 ; 43: 1317-1323
14. Clements A, Tull D, Jenney AW, et al. Secondary acylation of Klebsiella pneumoniae lipopolysaccharide contributes to sensitivity to antibacterial peptides. J Biol Chem. 2007 ; 282: 15569-15577
15. Wiegand I, Hilpert K, Hancock RE. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc. 2008 ; 3: 163-175
16. EUCAST ECoAST. Breakpoint tables for interpretation of MICs and zone diameters. In: Testing ECoAS. Version 13, 5 January 2011.
17. Darveau RP, Hancock RE. Procedure for isolation of bacterial lipopolysaccharides from both smooth and rough Pseudomonas aeruginosa and Salmonella typhimurium strains. J Bacteriol. 1983 ; 155: 831-838
18. Tsai CM, Frasch CE. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal Biochem. 1982 ; 119: 115-119
19. Lee CH, Tsai CM. Quantification of bacterial lipopolysaccharides by the purpald assay: measuring formaldehyde generated from 2-keto-3-deoxyoctonate and heptose at the inner core by periodate oxidation. Anal Biochem. 1999 ; 267: 161-168
20. Soon RL, Velkov T, Chiu F, et al. Design, synthesis and evaluation of a new fluorescent probe for measuring polymyxin-lipopolysaccharide binding interactions. Anal Biochem. 2011 ; 409: 273-283
21. Vaara M, Vaara T. Outer membrane permeability barrier disruption by polymyxin in polymyxin-susceptible and -resistant Salmonella typhimurium. Antimicrob Agents Chemother. 1981 ; 19: 578-583
22. Helander IM, Mattila-Sandholm T. Fluorometric assessment of Gram-negative bacterial permeabilization. J Appl Microbiol. 2000 ; 88: 213-219
23. Velkov T, Lim ML, Horne J, et al. Characterization of lipophilic drug binding to rat intestinal fatty acid binding protein. Mol Cell Biochem. 2009 ; 326: 87-95
24. Pristovsek P, Kidric J. Solution structure of polymyxins B and E and effect of binding to lipopolysaccharide: an NMR and molecular modeling study. J Med Chem. 1999 ; 42: 4604-4613
25. Pristovsek P, Kidric J. The search for molecular determinants of LPS inhibition by proteins and peptides. Curr Top Med Chem. 2004 ; 4: 1185-1201
26. Ferguson AD, Welte W, Hofmann E, et al. A conserved structural motif for lipopolysaccharide recognition by procaryotic and eucaryotic proteins. Structure. 2000 ; 8: 585-592
27. Bengoechea JA, Lindner B, Seydel U, Diaz R, Moriyon I. Yersinia pseudotuberculosis and Yersinia pestis are more resistant to bactericidal cationic peptides than Yersinia enterocolitica. Microbiology. 1998 ; 144: 1509-1515
28. Brandenburg K, David A, Howe J, et al. Temperature dependence of the binding of endotoxins to the polycationic peptides polymyxin B and its nonapeptide. Biophys J. 2005 ; 88: 1845-1858
29. Campos MA, Vargas MA, Regueiro V, et al. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect Immun. 2004 ; 72: 7107-7114
30. Groisman EA. How bacteria resist killing by host-defense peptides. Trends Microbiol. 1994 ; 2: 444-449
31. Peschel A. How do bacteria resist human antimicrobial peptides?. Trends Microbiol. 2002 ; 10: 179-186
32. Raetz CR, Reynolds CM, Trent MS, Bishop RE. Lipid A modification systems in Gram-negative bacteria. Annu Rev Biochem. 2007 ; 76: 295-329
33. Muller-Loennies S, Brade L, Brade H. Neutralizing and cross-reactive antibodies against enterobacterial lipopolysaccharide. Int J Med Microbiol. 2007 ; 297: 321-340
34. Holst O. The structures of core regions from enterobacterial lipopolysaccharides - an update. FEMS Microbiol Lett. 2007 ; 271: 3-11
35. Jansson PE, Lindberg AA, Lindberg B, Wollin R. Structural studies on the hexose region of the core in lipopolysaccharides from Enterobacteriaceae. Eur J Biochem. 1981 ; 115: 571-577
36. Vinogradov E, Frirdich E, MacLean LL, et al. Structures of lipopolysaccharides from Klebsiella pneumoniae. Eluicidation of the structure of the linkage region between core and polysaccharide O chain and identification of the residues at the non-reducing termini of the O chains. J Biol Chem. 2002 ; 277: 25070-25081
37. Vinogradov E, Perry MB. Structural analysis of the core region of the lipopolysaccharides from eight serotypes of Klebsiella pneumoniae. Carbohydr Res. 2001 ; 335: 291-296
38. Aucken HM, Pitt TL. Different O and K serotype distributions among clinical and environmental strains of Serratia marcescens. J Med Microbiol. 1998 ; 47: 1097-1104
39. Knirel Yu A, Vinogradov EV, Kocharova NA, et al. The structure of O-specific polysaccharides and serological classification of Pseudomonas aeruginosa (a review). Acta Microbiol Hung. 1988 ; 35: 3-24
40. Rocchetta HL, Burrows LL, Lam JS. Genetics of O-antigen biosynthesis in Pseudomonas aeruginosa. Microbiol Mol Biol Rev. 1999 ; 63: 523-553
41. Wilkinson SG. Composition and structure of lipopolysaccharides from Pseudomonas aeruginosa. Rev Infect Dis. 1983 ; 5 (Suppl. 5). S941 - S949
42. Knirel YA, Bystrova OV, Kocharova NA, et al. Conserved and variable structural features in the lipopolysaccharide of Pseudomonas aeruginosa. J Endotoxin Res. 2006 ; 12: 324-336
43. Vinogradov E, Lindner B, Seltmann G, et al. Lipopolysaccharides from Serratia marcescens possess one or two 4-amino-4-deoxy-L-arabinopyranose 1-phosphate residues in the lipid A and D-glycero-D-talo-oct-2-ulopyranosonic acid in the inner core region. Chemistry. 2006 ; 12: 6692-6700
44. Stenutz R, Weintraub A, Widmalm G. The structures of Escherichia coli O-polysaccharide antigens. FEMS Microbiol Rev. 2006 ; 30: 382-403
45. Hodate K, Bito Y. Temperature dependence of bactericidal action of polymyxin B. Microbiol Immunol. 1982 ; 26: 737-740
46. Leive L. Release of lipopolysaccharide by EDTA treatment of E. coli. Biochem Biophys Res Commun. 1965 ; 21: 290-296